Evidence map›Paper›PMID 41684323›Full record

ArticleEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin2026

Reduced neutralising antibody responses against emerging 2025/26 influenza A(H1N1)pdm09 subclade D.3.1 and A(H3N2) subclade K viruses among healthcare workers, Finland, August to October 2025.

Niina Ikonen, Anu Haveri, Erika Lindh, Oona Liedes, Saimi Vara, Sari H Pakkanen, Anu Kantele, Tea Nieminen, Veli-Jukka Anttila, Hanna Välimaa and 3 more

Abstract read
In one paragraph

Article in Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Niina IkonenThese authors contributed equally to this work and share first authorship.
Anu HaveriThese authors contributed equally to this work and share first authorship.
Erika LindhFinnish Institute for Health and Welfare, Department of Public Health, Helsinki, Finland.
Oona LiedesFinnish Institute for Health and Welfare, Department of Public Health, Helsinki, Finland.
Saimi VaraFinnish Institute for Health and Welfare, Department of Public Health, Helsinki, Finland.
Sari H PakkanenMeilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Anu KanteleUniversity of Helsinki, Department of Internal Medicine, Helsinki, Finland.
Tea NieminenHUS New Children's Hospital, Helsinki University Hospital, Helsinki, Finland.
Veli-Jukka AnttilaUniversity of Helsinki, Department of Internal Medicine, Helsinki, Finland.
Hanna VälimaaMeilahti Vaccine Research Center MeVac, Department of Infectious Diseases, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.
Merit MelinFinnish Institute for Health and Welfare, Department of Public Health, Helsinki, Finland.
Carita Savolainen-KopraFinnish Institute for Health and Welfare, Department of Public Health, Helsinki, Finland.
Hanna NohynekFinnish Institute for Health and Welfare, Department of Public Health, Helsinki, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

During autumn 2025, drifted influenza A(H3N2) subclade K and A(H1N1)pdm09 subclade D.3.1. and D.3.1.1 viruses were detected in Finland. We assessed antibody responses against 2024/25 vaccine and 2025/26 epidemic influenza A strains among 46 Finnish healthcare workers before and after influenza vaccination with the 2024/25 vaccine; this vaccine included identical A(H1N1)pdm09 but different A(H3N2) strains compared with the 2025/26 vaccine. Neutralising antibody responses were markedly reduced against the A(H3N2) subclade K virus and titres for certain A(H1N1)pdm09 strains were reduced.

Indexed as

Antibodies, NeutralizingAntibodies, ViralHealth PersonnelInfluenza A Virus, H1N1 SubtypeInfluenza A Virus, H3N2 SubtypeInfluenza, HumanInfluenza VaccinesAdultFemaleFinlandHemagglutination Inhibition TestsHumansMaleMiddle AgedNeutralization TestsSeasonsAntibodies, NeutralizingAntibodies, ViralInfluenza VaccinesA(H1N1)pdm09A(H3N2)healthcare workersneutralising antibodiesseasonal influenza vaccinesubclade K

Identifiers

PMID41684323
PMCPMC12905531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.